

# 2024 BRACE Award Venture Competition

*Bridging Research from Academia to Cancer Entrepreneurship*

*AFCR is proud to present the 2024 BRACE Award Venture Competition in collaboration with our partner organization, the AIM-HI Accelerator Fund.*

**APPLY NOW**

**[AIM-HIaccelerator.org/BRACE-Apply/](https://AIM-HIaccelerator.org/BRACE-Apply/)**

## CONTEST

- **Call for Application:** An online application form must be completed and submitted before the application deadline, **Friday, 15 March, 2024**.
- **Selection Committee** will screen all submitted applications to select semi-finalists based on the quality of responses.
- **Judging Committee** will evaluate each semi-finalists' presentation, followed by a Q&A session, and select top finalists.
- **Investment Committee** will conduct detailed due diligence research on the finalists to determine whether an investment will be made based on the technology platform merits, cancer patient impact, and potential for return.

## ELIGIBILITY

Early-stage oncology companies worldwide seeking pre-seed, seed, and Series A investments are eligible to apply. The applying company must have technology ownership in place, and its technology should be able to address **cancers prevalent in Asian populations**.

## BENEFITS

- Interacting with and **receiving valuable feedback** from the selection and judging committee members, who are key opinion leaders in the oncology field.
- Top finalists will be **awarded honorariums, recognized with certificates, and considered for further investment**, subject to rigorous due diligence conducted by our Investment Committee.
- The finalist who passes the due diligence process will be **eligible to receive investment** from AFCR, AIM-HI and co-investors; the process itself will also help the company assess and refine its IP and strategy, clinical development plan, and position itself well for other investors.
- The winners will **gain recognition and presentation opportunities** within the oncology research community, facilitating networking and collaboration opportunities with global cancer experts and investors.

